

# Anetta Undas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2714501/publications.pdf>

Version: 2024-02-01

214  
papers

4,455  
citations

159573

30  
h-index

149686

56  
g-index

215  
all docs

215  
docs citations

215  
times ranked

4530  
citing authors

#	ARTICLE	IF	CITATIONS
1	Isoprostane <sup>8</sup> and GDF <sup>15</sup> as novel markers of post <sup>PE</sup> syndrome: Relation with prothrombotic factors. European Journal of Clinical Investigation, 2022, 52, e13660.	3.4	3
2	Caprini VTE computerized risk assessment improves the use of thromboprophylaxis in hospitalized patients with pulmonary disorders. Advances in Clinical and Experimental Medicine, 2022, 31, 261-266.	1.4	0
3	Apolipoproteins and lipoprotein(a) as factors modulating fibrin clot properties in patients with severe aortic stenosis. Atherosclerosis, 2022, 344, 49-56.	0.8	5
4	8-Isoprostanes and Asymmetric Dimethylarginine as Predictors of Mortality in Patients Following Coronary Bypass Surgery: A Long-Term Follow-Up Study. Journal of Clinical Medicine, 2022, 11, 246.	2.4	3
5	Active factor XI is associated with the risk of cardiovascular events in stable coronary artery disease patients. Atherosclerosis, 2022, 346, 124-132.	0.8	10
6	Active FXI Can Independently Predict Ischemic Stroke in Anticoagulated Atrial Fibrillation Patients: A Cohort Study. Thrombosis and Haemostasis, 2022, 122, 1397-1406.	3.4	4
7	Knowledge about atrial fibrillation and anticoagulation affects the risk of clinical outcomes. Thrombosis Research, 2022, 213, 105-112.	1.7	5
8	Markers of NET formation and stroke risk in patients with atrial fibrillation: association with a prothrombotic state. Thrombosis Research, 2022, 213, 1-7.	1.7	13
9	Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: Association with lipoproteins and C-reactive protein. Vascular Pharmacology, 2022, 144, 106977.	2.1	8
10	Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study. International Journal of Hematology, 2021, 113, 190-198.	1.6	7
11	Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy: A cohort study. International Journal of Cardiology, 2021, 324, 78-83.	1.7	10
12	Afibrinogenemia caused by a novel homozygous missense mutation, FGB p.Cys241Tyr, in a male patient with recurrent intracranial bleeding: case report and review of literature. Haemophilia, 2021, 27, 26-32.	2.1	2
13	Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects. Thrombosis Research, 2021, 197, 1-7.	1.7	18
14	Cellular fibronectin promotes deep vein thrombosis in diet <sup>6</sup> -induced obese mice. Journal of Thrombosis and Haemostasis, 2021, 19, 814-821.	3.8	5
15	Von Willebrand factor in aortic or mitral valve stenosis and bleeding after heart valve surgery. Thrombosis Research, 2021, 198, 190-195.	1.7	1
16	Glycation and acetylation sites on fibrinogen in plasma fibrin clot of patients with type 2 diabetes: Effects of low-dose acetylsalicylic acid. Thrombosis Research, 2021, 198, 93-98.	1.7	3
17	Professor Franciszek Kokot and his successor, Professor Andrzej Januszewicz: the Polish Co-Chair of the Scientific Board of <i>Polish Archives of Internal Medicine</i>. Polish Archives of Internal Medicine, 2021, 131, 114-115.	0.4	0
18	Aortic valvular stenosis: Novel therapeutic strategies. European Journal of Clinical Investigation, 2021, 51, e13527.	3.4	4

#	ARTICLE	IF	CITATIONS
19	Fibrinolysis in Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 480-489.	2.7	7
20	Via Medica comes back as the publisher of <i>Kardiologia Polska</i> . <i>Kardiologia Polska</i> , 2021, 79, 371-372.	0.6	0
21	A new editor in <i>Polish Archives of Internal Medicine</i> : welcome to Professor Tomasz StompÅ³r. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 320-321.	0.4	0
22	Unsolved issues of The Efficacy and Safety of Edoxaban. , 2021, 25, 460-460.		1
23	Right ventricular echocardiographic parameters associated with prothrombotic abnormalities in normotensive patients with acute pulmonary embolism. <i>International Journal of Cardiology</i> , 2021, 333, 195-201.	1.7	1
24	Reduced-dose apixaban and dabigatran in patients with advanced liver cirrhosis and venous thromboembolism: a case series. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 762-765.	0.4	2
25	Fibrin Clot Properties in Atherosclerotic Vascular Disease: From Pathophysiology to Clinical Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 2999.	2.4	27
26	NOAC in patients with VTE and polycythemia vera or essential thrombocythemia. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, e743-e748.	1.9	2
27	The highest Impact Factor of <i>Kardiologia Polska</i> announced in June 2021: we did it!. <i>Kardiologia Polska</i> , 2021, 79, 723-724.	0.6	0
28	Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation. <i>Cardiovascular Diabetology</i> , 2021, 20, 191.	6.8	20
29	Diabetes concomitant to aortic stenosis is associated with increased expression of NF-Î²B and more pronounced valve calcification. <i>Diabetologia</i> , 2021, 64, 2562-2574.	6.3	13
30	Current treatment challenges in the COVID-19 pandemic. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 854-861.	0.4	20
31	Family History of Stroke is Associated with Greater Prevalence of Certain Risk Factors and Self-Reported Stroke Symptoms. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 106074.	1.6	1
32	Loose Fibrin Clot Structure and Increased Susceptibility to Lysis Characterize Patients with Central Acute Pulmonary Embolism: The Impact of Isolated Embolism. <i>Thrombosis and Haemostasis</i> , 2021, 121, 529-537.	3.4	7
33	Accelerated fibrin clot degradation is associated with arterial thromboembolism in patients following venous thrombosis: a cohort study. <i>Scientific Reports</i> , 2021, 11, 21003.	3.3	1
34	Thromboembolism and bleeding in patients with atrial fibrillation and stage 4 chronic kidney disease: impact of biomarkers. <i>Kardiologia Polska</i> , 2021, 79, 1086-1092.	0.6	11
35	Towards Personalized Therapy of Aortic Stenosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 1292.	2.5	2
36	<i>Kardiologia Polska</i> at the end of 2021: The pandemic and beyond. <i>Kardiologia Polska</i> , 2021, 79, 1299-1300.	0.6	0

#	ARTICLE	IF	CITATIONS
37	New publisher of Kardiologia Polska: what do we hope for in May 2021?. Kardiologia Polska, 2021, 79, 487.	0.6	0
38	Altered fibrin clot properties and fibrinolysis in patients with atrial fibrillation: practical implications. Europace, 2020, 22, 185-194.	1.7	8
39	Bleeding Tolerance Among Patients With Atrial Fibrillation on Oral Anticoagulation. Canadian Journal of Cardiology, 2020, 36, 500-508.	1.7	8
40	Clot Lysis Time Predicts Stroke During Anticoagulant Therapy in Patients with Atrial Fibrillation. Canadian Journal of Cardiology, 2020, 36, 119-126.	1.7	13
41	Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation. Clinical Research in Cardiology, 2020, 109, 426-434.	3.3	16
42	Fibrin Clot Properties and Thrombin Generation in Hypertrophic Cardiomyopathy. Thrombosis and Haemostasis, 2020, 120, 181-183.	3.4	3
43	Sex-specific alteration to $\alpha_2$ -antiplasmin incorporation in patients with type 2 diabetes. Thrombosis Research, 2020, 185, 55-62.	1.7	8
44	Identification of glycosylated and acetylated lysine residues in human $\alpha_2$ -antiplasmin. Biochemical and Biophysical Research Communications, 2020, 521, 19-23.	2.1	3
45	Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. Lupus, 2020, 29, 37-44.	1.6	31
46	Coagulation factors and fibrinolytic activity in the left atrial appendage and other heart chambers in patients with atrial fibrillation: is there a local intracardiac prothrombotic state? (HEART-CLOT) Tj ETQq0 0 0 rgBT / Overlock 108f 50 377	1.6	108
47	Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. The Cochrane Library, 2020, 10, CD012169.	2.8	18
48	Effect of enoxaparin on plasma fibrin clot properties and fibrin structure in patients with acute pulmonary embolism. Vascular Pharmacology, 2020, 133-134, 106783.	2.1	7
49	Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties. Journal of Proteomics, 2020, 229, 103946.	2.4	14
50	Interaction between functional polymorphisms in FCER1A and TLR2 and the severity of atopic dermatitis. Human Immunology, 2020, 81, 709-713.	2.4	5
51	Citrullinated histone H3, a marker of extracellular trap formation, is increased in blood of stable asthma patients. Clinical and Translational Allergy, 2020, 10, 31.	3.2	20
52	Prothrombotic fibrin clot properties associated with NETs formation characterize acute pulmonary embolism patients with higher mortality risk. Scientific Reports, 2020, 10, 11433.	3.3	30
53	Chronic Kidney Disease and Its Impact on a Prothrombotic State in Patients with Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 2476.	2.4	9
54	Impaired Fibrinolysis in Patients with Isolated Aortic Stenosis is Associated with Enhanced Oxidative Stress. Journal of Clinical Medicine, 2020, 9, 2002.	2.4	15

#	ARTICLE	IF	CITATIONS
55	Acceptance of a potential major bleeding among patients with venous thromboembolism on long-term oral anticoagulation: the knowledge of the disease and therapy matters. <i>Thrombosis Research</i> , 2020, 193, 116-121.	1.7	3
56	Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves. <i>Vascular Pharmacology</i> , 2020, 130, 106679.	2.1	9
57	Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 92.	6.8	40
58	Delayed Thrombin Generation Is Associated with Minor Bleedings in Venous Thromboembolism Patients on Rivaroxaban: Usefulness of Calibrated Automated Thrombography. <i>Journal of Clinical Medicine</i> , 2020, 9, 2018.	2.4	7
59	Plasma Fibrin Clot Properties as Determinants of Bleeding Time in Human Subjects: Association with Histidine-Rich Glycoprotein. <i>Disease Markers</i> , 2020, 2020, 1-11.	1.3	5
60	A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause. <i>Thrombosis Research</i> , 2020, 187, 32-38.	1.7	6
61	Elevated Lactate Levels in Acute Pulmonary Embolism Are Associated with Prothrombotic Fibrin Clot Properties: Contribution of NETs Formation. <i>Journal of Clinical Medicine</i> , 2020, 9, 953.	2.4	22
62	Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 47-58.	0.4	11
63	Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. <i>Kardiologia Polska</i> , 2020, 78, 105-116.	0.6	9
64	Guidance for anticoagulation management in venous thromboembolism during the coronavirus disease 2019 pandemic in Poland: an expert opinion of the Section on Pulmonary Circulation of the Polish Cardiac Society. <i>Kardiologia Polska</i> , 2020, 78, 642-646.	0.6	16
65	Polish Archives of Internal Medicine in the coronavirus disease 2019 pandemic. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 263-263.	0.4	0
66	A new impact factor of <i>Kardiologia Polska</i> . <i>Kardiologia Polska</i> , 2020, 78, 653-654.	0.6	0
67	Efficacy and safety of non-vitamin K antagonist oral anticoagulants in very elderly patients with atrial fibrillation: a single-center experience. <i>Kardiologia Polska</i> , 2020, 78, 154-157.	0.6	2
68	Cellular Fibronectin Promotes Deep Vein Thrombosis in Obese Mice. <i>Blood</i> , 2020, 136, 19-20.	1.4	0
69	Prothrombotic fibrin clot properties are associated with post-discharge venous thromboembolism in acutely ill medical patients. <i>Thrombosis Research</i> , 2019, 182, 141-149.	1.7	2
70	Prothrombotic clot properties can predict venous ulcers in patients following deep vein thrombosis: a cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 603-609.	2.1	8
71	Genetic and clinical characterization of congenital fibrinogen disorders in Polish patients: Identification of three novel fibrinogen gamma chain mutations. <i>Thrombosis Research</i> , 2019, 182, 133-140.	1.7	19
72	Plasma fibrin clot proteomics in healthy subjects: Relation to clot permeability and lysis time. <i>Journal of Proteomics</i> , 2019, 208, 103487.	2.4	24

#	ARTICLE	IF	CITATIONS
73	Fibrin biofilm can be detected on intracoronary thrombi aspirated from patients with acute myocardial infarction. <i>Cardiovascular Research</i> , 2019, 115, 1026-1028.	3.8	9
74	Polyhedral erythrocytes in intracoronary thrombus and their association with reperfusion in myocardial infarction. <i>Clinical Research in Cardiology</i> , 2019, 108, 950-962.	3.3	14
75	Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA <sub>2</sub> DS <sub>2</sub> -VASc Score (Beyond Sex). <i>Canadian Journal of Cardiology</i> , 2019, 35, 634-643.	1.7	13
76	A Prothrombotic State in Patients With a History of Left Ventricular Thrombus. <i>American Journal of Cardiology</i> , 2019, 123, 1358-1363.	1.6	6
77	Improving fibrinolysis in venous thromboembolism: impact of fibrin structure. <i>Expert Review of Hematology</i> , 2019, 12, 597-607.	2.2	12
78	Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study. <i>Vascular Pharmacology</i> , 2019, 120, 106567.	2.1	9
79	Increased activity of lipoprotein-associated phospholipase A2 in non-severe asthma. <i>Allergology International</i> , 2019, 68, 450-455.	3.3	8
80	High prevalence of inherited thrombophilia and antiphospholipid syndrome in myocardial infarction with non-obstructive coronary arteries: Comparison with cryptogenic stroke. <i>International Journal of Cardiology</i> , 2019, 290, 1-6.	1.7	35
81	Predictors of neutrophil extracellular traps markers in type 2 diabetes mellitus: associations with a prothrombotic state and hypofibrinolysis. <i>Cardiovascular Diabetology</i> , 2019, 18, 49.	6.8	47
82	NETosis is associated with the severity of aortic stenosis: Links with inflammation. <i>International Journal of Cardiology</i> , 2019, 286, 121-126.	1.7	20
83	Decreased Levels of Histidine-Rich Glycoprotein in Advanced Lung Cancer: Association with Prothrombotic Alterations. <i>Disease Markers</i> , 2019, 2019, 1-7.	1.3	17
84	Altered fibrin clot properties in advanced lung cancer: strong impact of cigarette smoking. <i>Medical Oncology</i> , 2019, 36, 37.	2.5	6
85	Restenosis is associated with prothrombotic plasma fibrin clot characteristics in endovascularly treated patients with critical limb ischemia. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 540-549.	2.1	5
86	Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non-recurrent disease. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 618-626.	3.8	24
87	High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50 years using the standardized protocol for thrombophilia screening. <i>Thrombosis Research</i> , 2019, 176, 67-73.	1.7	8
88	Plasma Fibrin Clot Properties Are Unfavorably Altered in Women following Venous Thromboembolism Associated with Combined Hormonal Contraception. <i>Disease Markers</i> , 2019, 2019, 1-9.	1.3	4
89	MPI-CDG with transient hypoglycosylation and antithrombin deficiency. <i>Haematologica</i> , 2019, 104, e79-e82.	3.5	12
90	Plasma Protein Oxidation as a Determinant of Impaired Fibrinolysis in Type 2 Diabetes. <i>Thrombosis and Haemostasis</i> , 2019, 119, 213-222.	3.4	14

#	ARTICLE	IF	CITATIONS
91	Altered Fibrin Clot Properties Predict Stroke and Bleedings in Patients With Atrial Fibrillation on Rivaroxaban. <i>Stroke</i> , 2019, 50, 185-188.	2.0	8
92	Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 8-15.	2.1	14
93	Plasma clot permeability and lysability determined on rivaroxaban and clinical outcomes in patients with venous thromboembolism: a cohort study. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 377-385.	0.4	11
94	Fibrinogen Å³dÅº: a new cause of dysfibrinogenemia associated with recurrent thromboembolic arterial events. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 934-935.	0.4	1
95	Determination and interpretation of MTHFR gene mutations in gynecology and internal medicine. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 728-732.	0.4	5
96	Congenital structural and functional fibrinogen disorders: a primer for internists. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 913-920.	0.4	10
97	The ORBIT bleeding score is associated with lysis and permeability of fibrin clots. <i>Kardiologia Polska</i> , 2019, 77, 1182-1185.	0.6	3
98	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and colorectal cancer: a single-center experience. <i>Kardiologia Polska</i> , 2019, 77, 1186-1189.	0.6	4
99	How to improve the management of a patient with HIT? Comments on a case report by GÅ¼ner A. et al.. <i>Anatolian Journal of Cardiology</i> , 2019, 22, 339.	0.9	0
100	Atrial fibrillation and rapid atrial pacing are linked to enhanced inflammation and altered fibrinolysis in patients undergoing pulmonary vein isolation. <i>Kardiologia Polska</i> , 2019, 77, 386-388.	0.6	3
101	Welcome to Medycyna Praktyczna: the Editor's comments. <i>Kardiologia Polska</i> , 2019, 77, 413-414.	0.6	0
102	Continuous growth of the journal. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 362-364.	0.4	0
103	Vascular Ehlers-Danlos syndrome in 2 Polish patients: identification of 2 novel COL3A1 gene mutations. <i>Kardiologia Polska</i> , 2019, 77, 1070-1073.	0.6	2
104	<i>Kardiologia Polska</i> in 2019 and a look into the future. <i>Kardiologia Polska</i> , 2019, 77, 1117-1118.	0.6	0
105	Elevated thrombin generation and factor VIII activity during angioedema attack in patients with hereditary C1 inhibitor deficiency. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 936-938.	0.4	0
106	Reduced plasma fibrin clot permeability is associated with recurrent thromboembolic events in patients with antiphospholipid syndrome. <i>Rheumatology</i> , 2018, 57, 1340-1349.	1.9	11
107	Altered Plasma Clot Properties and Trauma-Related Venous Thromboembolism despite Thromboprophylaxis. <i>Thrombosis and Haemostasis</i> , 2018, 47, 654-663.	3.4	4
108	Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People With Antiphospholipid Syndrome. <i>Stroke</i> , 2018, 49, .	2.0	1

#	ARTICLE	IF	CITATIONS
109	Impaired plasminogen binding in patients with venous thromboembolism: Association with protein carbonylation. <i>Thrombosis Research</i> , 2018, 163, 12-18.	1.7	3
110	Erythrocyte compression index is impaired in patients with residual vein obstruction. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 31-38.	2.1	7
111	Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study. <i>Blood</i> , 2018, 131, 797-807.	1.4	63
112	Altered fibrin clot properties in advanced lung cancer: impact of chemotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 6863-6872.	1.4	6
113	In silico thrombin and factor Xa generation profiles in adult patients after Fontan operation. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 236-240.	1.0	4
114	Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism. <i>Scientific Reports</i> , 2018, 8, 17301.	3.3	25
115	Polyhedrocytes in blood clots of type 2 diabetic patients with high cardiovascular risk: association with glycemia, oxidative stress and platelet activation. <i>Cardiovascular Diabetology</i> , 2018, 17, 146.	6.8	12
116	Impaired fibrinolysis in degenerative mitral and aortic valve stenosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 193-202.	2.1	3
117	Increased blood levels of cellular fibronectin in asthma: Relation to the asthma severity, inflammation, and prothrombotic blood alterations. <i>Respiratory Medicine</i> , 2018, 141, 64-71.	2.9	23
118	Altered structure and function of fibrinogen after cleavage by Factor VII Activating Protease (FSAP). <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3397-3406.	3.8	11
119	Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2018, 17, 29.	6.8	33
120	Real-life use of thromboprophylaxis in patients hospitalized for pulmonary disorders: A single-center retrospective study. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 237-243.	1.4	3
121	Non-classical and intermediate monocytes in patients following venous thromboembolism: Links with inflammation. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 28, 51-58.	1.4	13
122	Knowledge gaps in patients with venous thromboembolism: usefulness of a new questionnaire. <i>Polish Archives of Internal Medicine</i> , 2018, 129, 28-35.	0.4	6
123	Association of cardiac troponin I with prothrombotic alterations in atrial fibrillation. <i>Kardiologia Polska</i> , 2018, 76, 1106-1109.	0.6	12
124	Angiotensin-converting enzyme inhibitors modulate the activation of the tissue factor pathway within aortic valves in patients with aortic stenosis: Links between blood coagulation and inflammation. <i>Postępy Higieny I Medycyny Doswiadczalnej</i> , 2018, 72, 1208-1215.	0.1	1
125	Statins in prevention of venous thromboembolism. <i>Lancet Haematology</i> , the, 2017, 4, e61-e62.	4.6	2
126	Prothrombotic Fibrin Clot Phenotype Is Associated With Recurrent Pulmonary Embolism After Discontinuation of Anticoagulant Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 365-373.	2.4	45

#	ARTICLE	IF	CITATIONS
127	Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNF $\alpha$ , in Peripheral Blood. <i>Inflammation</i> , 2017, 40, 1225-1235.	3.8	32
128	Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 243, 244-250.	1.7	16
129	Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 438-442.	1.0	26
130	The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. <i>Thrombosis Research</i> , 2017, 152, 93-97.	1.7	49
131	Effects of ultra-low-dose versus standard hormone therapy on fibrinolysis and thrombin generation in postmenopausal women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 217, 77-82.	1.1	3
132	Fibrin Clot Permeability as a Predictor of Stroke and Bleeding in Anticoagulated Patients With Atrial Fibrillation. <i>Stroke</i> , 2017, 48, 2716-2722.	2.0	37
133	Impaired fibrinolysis and lower levels of plasma $\alpha$ 2-macroglobulin are associated with an increased risk of severe asthma exacerbations. <i>Scientific Reports</i> , 2017, 7, 11014.	3.3	11
134	Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials. <i>Pharmacological Research</i> , 2017, 124, 64-73.	7.1	4
135	Determination of Fibrinogen and Thrombin Time (TT). <i>Methods in Molecular Biology</i> , 2017, 1646, 105-110.	0.9	33
136	Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1739-1749.	3.4	20
137	Specific changes in circulating cytokines and growth factors induced by exercise stress testing in asymptomatic aortic valve stenosis. <i>PLoS ONE</i> , 2017, 12, e0173787.	2.5	8
138	Optimization of quantitative proteomic analysis of clots generated from plasma of patients with venous thromboembolism. <i>Clinical Proteomics</i> , 2017, 14, 38.	2.1	24
139	Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1440-1447.	3.4	27
140	Acute-phase proteins and oxidative stress in patients undergoing coronary artery bypass graft: comparison of cardioplegia strategy. <i>Kardiochirurgia i Torakochirurgia Polska</i> , 2017, 1, 16-21.	0.1	2
141	Interplay between elevated cellular fibronectin and plasma fibrin clot properties in type 2 diabetes. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1671-1678.	3.4	9
142	Genetic characterization of antithrombin, protein C and protein S deficiencies in Polish patients. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 512-523.	0.4	23
143	Plasma fibrin clot structure and thromboembolism: clinical implications. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 873-881.	0.4	59
144	Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2017, 23, 4796.	3.3	10

#	ARTICLE	IF	CITATIONS
145	Prediction of unstable anticoagulation with acenocoumarol versus warfarin in atrial fibrillation. <i>Cardiology Journal</i> , 2017, 24, 477-483.	1.2	5
146	Neutrophil extracellular traps formation in patients with eosinophilic granulomatosis with polyangiitis: association with eosinophilic inflammation. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 27-32.	0.8	8
147	Determinants of hypofibrinolysis in patients with digestive tract cancer. <i>Przegląd Gastroenterologiczny</i> , 2016, 2, 104-110.	0.7	5
148	Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke. <i>Archives of Medical Science</i> , 2016, 5, 1000-1007.	0.9	12
149	Preoperative values of inflammatory markers predict clinical outcomes in patients after CABG, regardless of the use of cardiopulmonary bypass. <i>Indian Heart Journal</i> , 2016, 68, S10-S15.	0.5	21
150	How to Assess Fibrinogen Levels and Fibrin Clot Properties in Clinical Practice?. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 381-388.	2.7	49
151	Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2016, 223, 186-194.	1.7	29
152	Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism. <i>Vascular Pharmacology</i> , 2016, 87, 242-247.	2.1	45
153	Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 1872-1878.	2.0	20
154	Fibrin structure in organized thrombotic material removed during pulmonary artery endarterectomy: the effect of vessel calibre. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 212-217.	2.1	8
155	On antithrombotic mechanisms of statins: Are they relevant in intracerebral or subarachnoid bleedings?. <i>Neurologia i Neurochirurgia Polska</i> , 2016, 50, 141-142.	1.2	0
156	Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 1321-1330.	1.4	15
157	Practical considerations on non-vitamin K oral anticoagulants in patients with high body weight. <i>Anatolian Journal of Cardiology</i> , 2016, 16, 220.	0.9	0
158	Commentary to the article: "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients". <i>Kardiologia Polska</i> , 2016, 74, 504-505.	0.6	0
159	Induction therapy alters plasma fibrin clot properties in multiple myeloma patients. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 621-627.	1.0	19
160	Association of the C-Reactive Protein Gene (CRP) rs1205 C>T Polymorphism with Aortic Valve Calcification in Patients with Aortic Stenosis. <i>International Journal of Molecular Sciences</i> , 2015, 16, 23745-23759.	4.1	12
161	Increased Plasma Clot Permeability and Susceptibility to Lysis Are Associated with Heavy Menstrual Bleeding of Unknown Cause: A Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0125069.	2.5	17
162	Increased Oxidation as an Additional Mechanism Underlying Reduced Clot Permeability and Impaired Fibrinolysis in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-8.	2.3	21

#	ARTICLE	IF	CITATIONS
163	Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: Association with thrombin generation, endothelial injury and platelet activation. <i>Thrombosis Research</i> , 2015, 136, 408-414.	1.7	37
164	Exercise stress testing enhances blood coagulation and impairs fibrinolysis in asymptomatic aortic valve stenosis. <i>Journal of Cardiology</i> , 2015, 65, 501-507.	1.9	4
165	Shotgun analysis of plasma fibrin clot-bound proteins in patients with acute myocardial infarction. <i>Thrombosis Research</i> , 2015, 135, 754-759.	1.7	10
166	The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. <i>Thrombosis Research</i> , 2015, 135, 1035-1036.	1.7	46
167	Low fasting glucose is associated with enhanced thrombin generation and unfavorable fibrin clot properties in type 2 diabetic patients with high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2015, 14, 44.	6.8	19
168	Preoperative platelet aggregation predicts perioperative blood loss and rethoracotomy for bleeding in patients receiving dual antiplatelet treatment prior to coronary surgery. <i>Thrombosis Research</i> , 2015, 136, 519-525.	1.7	19
169	Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3 days of treatment: Relation to coagulation factors and thrombin generation. <i>Thrombosis Research</i> , 2015, 136, 832-838.	1.7	20
170	Protein N-linked homocysteine is associated with recurrence of venous thromboembolism. <i>Thrombosis Research</i> , 2015, 136, 911-916.	1.7	4
171	Unfavorably Altered Fibrin Clot Properties in Patients with Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Association with Thrombin Generation and Eosinophilia. <i>PLoS ONE</i> , 2015, 10, e0142167.	2.5	10
172	Determinants of Elevated Levels of Natural Anticoagulants in Healthy Subjects. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 791-800.	1.4	6
173	Arterial and Venous Thromboembolism in Chronic Obstructive Pulmonary Disease: From Pathogenic Mechanisms to Prevention and Treatment. <i>Pneumonologia i Alergologia Polska</i> , 2015, 83, 485-494.	0.6	14
174	Altered fibrin clot structure/function in patients with antiphospholipid syndrome: association with thrombotic manifestation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 287-296.	3.4	27
175	Modulation of Inflammatory and Hemostatic Markers in Obstructive Sleep Apnea Patients Treated with Mandibular Advancement Splints: A Parallel, Controlled Trial. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 255-262.	2.6	35
176	The Relationship between Total Serum IgE Levels and Atopic Sensitization in Subjects with or without Atopic Dermatitis. <i>Allergy International</i> , 2014, 63, 485-486.	3.3	3
177	Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2014, 44, 557-566.	3.4	21
178	Weight Reduction Is Associated With Increased Plasma Fibrin Clot Lysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 832-837.	1.7	7
179	PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy. <i>Thrombosis Research</i> , 2014, 134, 199-201.	1.7	24
180	Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 434-439.	2.6	25

#	ARTICLE	IF	CITATIONS
181	Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 1284-1290.	0.8	80
182	Coronary thrombus composition: Links with inflammation, platelet and endothelial markers. <i>Atherosclerosis</i> , 2014, 237, 555-561.	0.8	64
183	Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications. <i>Thrombosis Research</i> , 2014, 134, 510-517.	1.7	13
184	Fibrin clot properties and their modulation in thrombotic disorders. <i>Thrombosis and Haemostasis</i> , 2014, 112, 32-42.	3.4	117
185	Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. <i>Thrombosis and Haemostasis</i> , 2014, 111, 685-693.	3.4	59
186	Calcification of aortic human valves studied <i>in situ</i> by Raman microimaging: following mineralization from small grains to big deposits. <i>Journal of Raman Spectroscopy</i> , 2013, 44, 1222-1229.	2.5	20
187	Altered plasma fibrin clot properties in patients with digestive tract cancers: Links with the increased thrombin generation. <i>Thrombosis Research</i> , 2013, 131, 262-267.	1.7	23
188	Atherosclerosis and venous thromboembolism – similarities. <i>Kardiologia Polska</i> , 2013, 71, 1223-1228.	0.6	9
189	Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 189-194.	1.0	15
190	Plasma fibrin clot properties in arterial hypertension and their modification by antihypertensive medication. <i>Thrombosis Research</i> , 2012, 130, 99-103.	1.7	29
191	Factor XIII expression within aortic valves and its plasma activity in patients with aortic stenosis: association with severity of disease. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1172-1179.	3.4	18
192	A history of early stent thrombosis is associated with prolonged clot lysis time. <i>Thrombosis and Haemostasis</i> , 2012, 107, 513-520.	3.4	37
193	Does Diabetes Accelerate the Progression of Aortic Stenosis through Enhanced Inflammatory Response within Aortic valves?. <i>Inflammation</i> , 2012, 35, 834-840.	3.8	44
194	Active tissue factor and activated factor XI in patients with acute ischemic cerebrovascular events. <i>European Journal of Clinical Investigation</i> , 2012, 42, 123-129.	3.4	24
195	Altered fibrin clot properties in patients with premature peripheral artery disease. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 608-616.	0.4	11
196	Thrombin generation in chronic obstructive pulmonary disease: Dependence on plasma factor composition. <i>Thrombosis Research</i> , 2011, 128, e24-e28.	1.7	37
197	Circulating activated factor XI and active tissue factor as predictors of worse prognosis in patients following ischemic cerebrovascular events. <i>Thrombosis Research</i> , 2011, 128, e62-e66.	1.7	32
198	Fibrin Clot Structure and Function. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, e88-99.	2.4	422

#	ARTICLE	IF	CITATIONS
199	Acquired dysfibrinogenemia in atherosclerotic vascular disease. , 2011, 121, 310-9.		6
200	Shorter preoperative fibrin clot lysis time predisposes to higher chest tube drainage in patients undergoing elective coronary artery bypass grafting surgery. Blood Coagulation and Fibrinolysis, 2010, 21, 380-381.	1.0	11
201	Altered fibrin clot properties in patients with chronic heart failure and sinus rhythm: a novel prothrombotic mechanism. Heart, 2010, 96, 1114-1118.	2.9	28
202	Architecture of a pulmonary thrombus removed during embolectomy in a patient with acute pulmonary embolism. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, e40-e41.	0.8	9
203	Fibrin clot properties in acute ischemic stroke: relation to neurological deficit. Thrombosis Research, 2010, 125, 357-361.	1.7	83
204	Effect of cigarette smoking on plasma fibrin clot permeability and susceptibility to lysis. Thrombosis and Haemostasis, 2009, 102, 1289-1291.	3.4	40
205	Altered Fibrin Clot Structure/Function in Patients With Cryptogenic Ischemic Stroke. Stroke, 2009, 40, 1499-1501.	2.0	113
206	Systemic blood coagulation activation in acute coronary syndromes. Blood, 2009, 113, 2070-2078.	1.4	61
207	Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood, 2009, 114, 4272-4278.	1.4	226
208	Architecture of intra-atrial thrombi in patients with severe mitral stenosis. Journal of Heart Valve Disease, 2009, 18, 496-8.	0.5	3
209	Factor XIa and tissue factor activity in patients with coronary artery disease. Thrombosis and Haemostasis, 2008, 99, 142-149.	3.4	76
210	Blood coagulation at the site of microvascular injury: effects of low-dose aspirin. Blood, 2001, 98, 2423-2431.	1.4	84
211	Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation. Circulation, 2001, 103, 2248-2253.	1.6	255
212	Relationship between bleeding time, aspirin and the PIA1/A2 polymorphism of platelet glycoprotein IIIa. British Journal of Haematology, 2000, 110, 965-967.	2.5	120
213	Pathogenesis of Vascular Disease in Hyperhomocysteinaemia. European Journal of Cardiovascular Prevention and Rehabilitation, 1998, 5, 239-247.	2.8	26
214	Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. The Cochrane Library, 0, , .	2.8	3